We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Homology Medicines Inc (FIXX) USD0.0001

Sell:$0.86 Buy:$0.86 Change: $0.0111 (1.30%)
NASDAQ:0.28%
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Sell:$0.86
Buy:$0.86
Change: $0.0111 (1.30%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Sell:$0.86
Buy:$0.86
Change: $0.0111 (1.30%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.

Contact details

Address:
1 Patriots Park
BEDFORD
01730-2343
United States
Telephone:
+1 (781) 3017277
Website:
https://www.homologymedicines.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FIXX
ISIN:
US4380831077
Market cap:
$50.57 million
Shares in issue:
58.13 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Arthur Tzianabos
    Executive Chairman of the Board
  • Paul Alloway
    President, Chief Operating Officer, Company Secretary
  • Charles Michaud
    Principal Financial Officer, Principal Accounting Officer, Vice President, Corporate Controller, Treasurer
  • Michael Blum
    Chief Commercial Officer
  • Julie Jordan
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.